Does Cosentyx Reduce COVID-19 Vaccine Effectiveness?
Cosentyx (secukinumab), an IL-17 inhibitor for psoriasis and other inflammatory conditions, can impair COVID-19 vaccine responses. Studies show patients on Cosentyx produce lower antibody levels after mRNA vaccines like Pfizer-BioNTech or Moderna compared to healthy controls. For instance, one analysis found secukinumab users had 40-60% lower anti-spike IgG titers post-vaccination, though T-cell responses remained partially intact.[1][2]
How Does Cosentyx Interfere with Vaccines?
IL-17 blockade by Cosentyx dampens inflammation-driven immune signaling, which indirectly weakens B-cell activation and antibody production needed for humoral immunity. This effect is more pronounced after the second dose but doesn't fully eliminate protection—some neutralizing antibodies still form against variants like Delta.[3] Live vaccines are contraindicated due to infection risk, but COVID-19 shots (mRNA, viral vector) are inactivated or synthetic.
Real-World Data from Studies
A 2022 multicenter study of 198 rheumatic patients on biologics, including secukinumab, reported seropositivity rates of 85% post-two doses—lower than non-biologic groups (95%)—with waning faster over six months.[4] Booster doses improved responses modestly (to ~90% seropositivity). No increased breakthrough infections tied directly to Cosentyx in vaccinated cohorts, but data gaps exist for Omicron-era vaccines.[1][5]
Recommendations for Patients on Cosentyx
Guidelines from the American College of Rheumatology advise vaccinating biologic users without pausing therapy, as benefits outweigh risks. Monitor antibody levels if high-risk (e.g., elderly, comorbidities); consider boosters or additional doses. Consult providers for timing—vaccinate during stable disease control.[6] No specific Cosentyx patent issues affect vaccine access; it's Novartis-manufactured with patents expiring ~2028 in key markets.[7]
Compared to Other Biologics
| Biologic | Vaccine Antibody Impact | Notes |
|----------|--------------------------|--------|
| Cosentyx (IL-17i) | Moderate reduction | T-cells less affected |
| Humira (TNF-i) | Mild-moderate | Better humoral response |
| Stelara (IL-12/23i) | Moderate | Similar to Cosentyx |
| JAK inhibitors | Highest reduction | Strongest efficacy concern |
TNF inhibitors like Humira show less interference than IL-17/IL-23 blockers.[2][4]
Sources
[1] RMD Open: Immunogenicity of COVID-19 vaccines in rheumatic diseases
[2] Annals of Rheumatic Diseases: Biologics and vaccine response
[3] Journal of Allergy and Clinical Immunology: IL-17 inhibition effects
[4] Lancet Rheumatology: Seroprotection in autoimmune patients
[5] ACR Guidelines: COVID-19 Vaccine in Rheumatic Diseases
[6] EULAR Recommendations: Vaccination in Rheumatic Diseases
[7] DrugPatentWatch: Cosentyx Patents